Skip to main content

Table 1 Baseline characteristics

From: Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation

Characteristic ≥ 50% stenosis (n = 228) < 50% stenosis (n = 400)
White/Caucasian (%) 81 85
Age (years)* 62 ± 12 56 ± 11
Past medical history (%)   
   Diabetes mellitus* 38 16
   Hypertension* 67 54
   Dyslipidemia* 63 40
Systolic blood pressure (mmHg) 138 ± 22 136 ± 21
Diastolic blood pressure (mmHg) 77 ± 11 77 ± 11
Body mass index (kg/m2) 29.1 ± 6.4 29.8 ± 6.8
Waist circumference (in) 36 ± 8 36 ± 7
Cigarette smoking (%)   
   Currently 22 19
   Past 37 33
Menopausal status (%)*   
   Pre-menopausal 13 19
   Peri-menopausal 4 10
   Post-menopausal 82 70
Family history of premature CAD (%) 65 66
Current medication use (%)   
   Aspirin* 75 49
   Statin* 37 22
   ACE-inhibitor* 29 22
   β-blocker* 50 34
History of HRT (%)* 40 54
CRP (n = 547; median, IQR) 0.37, 0.17–0.97 0.36, 0.16–0.84
SAA (n = 519; median, IQR)* 0.66, 0.36–1.15 0.55, 0.31–0.94
IL-6 (n = 547; median, IQR) 3.37, 1.85–6.87 2.79, 1.72–4.61
  1. Abbreviations: ACE, angiotensin-converting enzyme; CAD, coronary artery disease; HRT, hormone replacement therapy; IQR, interquartile range; CRP, C-reactive protein; SAA, serum amyloid A; IL-6, interleukin-6
  2. Values presented as means+SD unless otherwise specified
  3. *P < 0.05 for comparison between > 50% stenosis and < 50% stenosis; for CRP, SAA, and IL-6 based on Wilcoxon rank-sum test
  4. History of high cholesterol or use of lipid-lowering medication